From Sequence to Therapy: Innovations in Oligonucleotide and Genome Editing Medicines
Laura Sepp-Lorenzino, PhD, Biotech Executive, Board Member and Industry Advisor, GNMmeds LLC
#genesequencing #oligonucleotides #geneediting #antisense oligonucleotides #siRNA #genomeeditingplatforms #drugdeliverystrategies
Why this is critically important to the oligonucleotide / genome editing industry
We are in the rise of programmable therapeutics, a change in the landscape which is transforming the treatment paradigms for both genetic and acquired diseases. In this keynote session, Dr. Sepp-Lorenzino reviews the latest advances in antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and genome editing platforms to highlight the delivery strategies that enable tissue-specific targeting and effective intracellular trafficking.
The landscape for genome editing is rapidly adjusting to this new world. Are you ready for what’s next? This is your chance to discover how you can adapt with the latest technologies and refine your delivery strategies to position yourself for success. Examine case studies and pipeline developments to better understand how innovation will pave the way for durable, disease-modifying diseases across the board.
How will it help your career?
Obtain practical insights into translational challenges and successes of bringing oligonucleotide and genome editing therapies to the clinic. You’ll discover how to apply delivery and targeting strategies for enhanced therapeutic impact, better understand the convergence of oligonucleotide and genome editing modalities, and enhance your ability to translate early-stage research into clinically meaningful treatments.
Ideal for those working in research and development, oligonucleotide chemistry, translational medicine, therapeutic delivery, and clinical operations.
